KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Inventory (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 10 years of Inventory data on record, last reported at $22.9 million in Q1 2025.

  • For Q1 2025, Inventory fell 62.95% year-over-year to $22.9 million; the TTM value through Mar 2025 reached $22.9 million, down 62.95%, while the annual FY2023 figure was $35.8 million, 439.77% up from the prior year.
  • Inventory reached $22.9 million in Q1 2025 per ACAD's latest filing, down from $71.5 million in the prior quarter.
  • Across five years, Inventory topped out at $71.5 million in Q2 2024 and bottomed at $5.8 million in Q3 2022.
  • Average Inventory over 5 years is $22.7 million, with a median of $10.3 million recorded in 2021.
  • Peak YoY movement for Inventory: soared 916.18% in 2024, then tumbled 62.95% in 2025.
  • A 5-year view of Inventory shows it stood at $7.9 million in 2021, then decreased by 15.8% to $6.6 million in 2022, then skyrocketed by 439.77% to $35.8 million in 2023, then surged by 99.68% to $71.5 million in 2024, then crashed by 67.92% to $22.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $22.9 million in Q1 2025, $71.5 million in Q2 2024, and $61.9 million in Q1 2024.